200 related articles for article (PubMed ID: 37017995)
21. Molecular Predictors of Radiotherapy Response in Sarcoma.
Chan CH; Wong P
Curr Treat Options Oncol; 2016 Jan; 17(1):2. PubMed ID: 26714494
[TBL] [Abstract][Full Text] [Related]
22. Sarcoma treatment in the era of molecular medicine.
Grünewald TG; Alonso M; Avnet S; Banito A; Burdach S; Cidre-Aranaz F; Di Pompo G; Distel M; Dorado-Garcia H; Garcia-Castro J; González-González L; Grigoriadis AE; Kasan M; Koelsche C; Krumbholz M; Lecanda F; Lemma S; Longo DL; Madrigal-Esquivel C; Morales-Molina Á; Musa J; Ohmura S; Ory B; Pereira-Silva M; Perut F; Rodriguez R; Seeling C; Al Shaaili N; Shaabani S; Shiavone K; Sinha S; Tomazou EM; Trautmann M; Vela M; Versleijen-Jonkers YM; Visgauss J; Zalacain M; Schober SJ; Lissat A; English WR; Baldini N; Heymann D
EMBO Mol Med; 2020 Nov; 12(11):e11131. PubMed ID: 33047515
[TBL] [Abstract][Full Text] [Related]
23. The diagnosis, classification, and treatment of sarcoma in this era of artificial intelligence and immunotherapy.
Crombé A; Roulleau-Dugage M; Italiano A
Cancer Commun (Lond); 2022 Dec; 42(12):1288-1313. PubMed ID: 36260064
[TBL] [Abstract][Full Text] [Related]
24. Sarcomas: Immune biomarker expression and checkpoint inhibitor trials.
Zhu MMT; Shenasa E; Nielsen TO
Cancer Treat Rev; 2020 Dec; 91():102115. PubMed ID: 33130422
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis.
Ito M; Barys L; O'Reilly T; Young S; Gorbatcheva B; Monahan J; Zumstein-Mecker S; Choong PF; Dickinson I; Crowe P; Hemmings C; Desai J; Thomas DM; Lisztwan J
Clin Cancer Res; 2011 Feb; 17(3):416-26. PubMed ID: 21159888
[TBL] [Abstract][Full Text] [Related]
26. Role of Immunotherapy in Sarcomas.
Dalal S; Shan KS; Thaw Dar NN; Hussein A; Ergle A
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279265
[TBL] [Abstract][Full Text] [Related]
27. The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma.
Ryan CW; Desai J
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714556
[TBL] [Abstract][Full Text] [Related]
28. Changing concepts in the pathological basis of soft tissue and bone sarcoma treatment.
Hogendoorn PC; Collin F; Daugaard S; Dei Tos AP; Fisher C; Schneider U; Sciot R;
Eur J Cancer; 2004 Jul; 40(11):1644-54. PubMed ID: 15251152
[TBL] [Abstract][Full Text] [Related]
29. Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas.
Suehara Y; Kohsaka S; Yamaguchi S; Hayashi T; Kurihara T; Sano K; Sasa K; Akaike K; Ueno T; Kojima S; Ikegami M; Mizuno S; Okubo T; Kim Y; Kaneko K; Saito T; Kato S; Mano H
Clin Orthop Relat Res; 2020 Nov; 478(11):2461-2476. PubMed ID: 32567826
[TBL] [Abstract][Full Text] [Related]
30. The potentiality of immunotherapy for sarcomas: a summary of potential predictive biomarkers.
Liang J; Chen D; Chen L; She X; Zhang H; Xiao Y
Future Oncol; 2020 Jun; 16(17):1211-1223. PubMed ID: 32396026
[TBL] [Abstract][Full Text] [Related]
31. The current reality of soft tissue sarcomas: advances, controversies, areas for improvement, and promising new treatments.
Blay JY; Le Cesne A; Demetri GD
Expert Rev Anticancer Ther; 2020 Apr; 20(sup1):29-39. PubMed ID: 32349562
[No Abstract] [Full Text] [Related]
32. Immunotherapy and Biomarkers in Sarcoma.
Dajsakdipon T; Siripoon T; Ngamphaiboon N; Ativitavas T; Dejthevaporn T
Curr Treat Options Oncol; 2022 Mar; 23(3):415-438. PubMed ID: 35262852
[TBL] [Abstract][Full Text] [Related]
33. Next-generation sequencing for the management of sarcomas with no known driver mutations.
Vyse S; Thway K; Huang PH; Jones RL
Curr Opin Oncol; 2021 Jul; 33(4):315-322. PubMed ID: 33927108
[TBL] [Abstract][Full Text] [Related]
34. Novel pathways and molecular targets for the treatment of sarcoma.
Frith AE; Hirbe AC; Van Tine BA
Curr Oncol Rep; 2013 Aug; 15(4):378-85. PubMed ID: 23661264
[TBL] [Abstract][Full Text] [Related]
35. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
[No Abstract] [Full Text] [Related]
36. Homologous recombination repair deficiency as a therapeutic target in sarcoma.
Oza J; Doshi SD; Hao L; Musi E; Schwartz GK; Ingham M
Semin Oncol; 2020 Dec; 47(6):380-389. PubMed ID: 33183763
[TBL] [Abstract][Full Text] [Related]
37. TP53 in bone and soft tissue sarcomas.
Thoenen E; Curl A; Iwakuma T
Pharmacol Ther; 2019 Oct; 202():149-164. PubMed ID: 31276706
[TBL] [Abstract][Full Text] [Related]
38. [Not Available].
Blay JY
Bull Acad Natl Med; 2015 Jan; 199(1):41-60; discussion 60-1. PubMed ID: 27236877
[No Abstract] [Full Text] [Related]
39. Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas.
Martín-Broto J; Moura DS; Van Tine BA
Clin Cancer Res; 2020 Nov; 26(22):5801-5808. PubMed ID: 32601077
[TBL] [Abstract][Full Text] [Related]
40. Sarcomas of soft tissue and bone.
Mazanet R; Antman KH
Cancer; 1991 Aug; 68(3):463-73. PubMed ID: 2065265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
